medigraphic.com

2013, Number S1

<< Back Next >>

Revista Cubana de Angiología y Cirugía Vascular 2013; 14 (S1)

Prophylaxis of deep venous thromboembolic disease

Santos DY

Language: Spanish
References: 34
Page:
PDF size: 351.00 Kb.


ABSTRACT

Introduction: the incidence of venous thromboembolic disease is high in the general population and increases up to 100 times in hospitalized patients; hence, it is considered the first cause of preventable death at hospital. It bears high economic cost and sequelae, most of deaths are sudden or occur in the first two hours before the treatment could be effectively applied. There are enough reasons for the implementation of thromboprophylaxis.
Objective: to provide an updated review of the current recommendations on thromboprophylaxis.
Source of data: information was collected from Medline(200-2012) and the Cochrane Library clinical trial database. The key words were pulmonary thromboembolism, venous thrombosis and thromboflebitis, prevention of these diseases and controlled and randomized clinical trials. Results: there is a number of mechanical and pharmacological methods to prevent the disease and the most recommended are low molecular weight heparins and, in some specific situations, the new oral anticoagulants such a Rivaroxaban, Dabigatan and Apixaban.
Conclusions: the implementation of prophylactic strategies based on the best scientific evidence available will benefit the patients who are admitted to the hospitals; therefore, these centers must develop a line of strategy to address the prevention of thromboembolic complications based on a thromboprophylactic policy aimed at high risk groups.


REFERENCES

  1. Botella F G. Reflexiones sobre la enfermedad tromboembólica venosa. An Med Interna (Madrid). 2003;20:447-50.

  2. Páramo A, Feliu J, Iglesias R, Ruiz de Gaona E, Lecumberri R. Profilaxis del tromboembolismo venoso: recomendaciones en pacientes médicos y sistema de alarma electrónica en pacientes hospitalizados. Rev Med Univ Navarra. 2006;50(1):17-23.

  3. Geerts WH, Bergqvist D, Pineo GF, Heit JA, Samama CH M, Lassen MR, et al. Prevention of venous thromboembolism. Chest. 2008 [cited 2010 Jun 8];113 (Supp 6):381S. Available from: http://chestjournal.chestpubs.org/content /133/6_suppl/381S.full.htm

  4. Heit JA, Silverstein MD, Mohr DN, Petterson TM, Lohse CM, O'Fallon WM. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001;86:452-63.

  5. Echegaray M, Alonso J, Aránzazu M, Abínzano M, Gonzalez C, Solano M. Tromboembolismo pulmonar: evolución a largo plazo y epidemiología clínica. An Med Interna (Madrid). 2003;20:451-6.

  6. Schmid-Schönbein GW, Takase S, Bergan JJ. New advances in the understanding of the pathophysiology of chronic venous insufficiency. Angiology. 2001; 52:S27-8.

  7. Berqvist D, Burmark VS, Frisell J, Hallbook T, Lindblad B, Risberg B. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg. 1986;73(3):204-8.

  8. Geerts WH, Heit JA, Clagget GP, Pineo GF, Colwell CW, Anderson FA Jr. Prevention of venous thromboembolism. Chest. 2001;119 (Suppl 1):132-75.

  9. Arregoitia Babiy A. Caracterización de pacientes fallecidos por TEP en unidades de atención al Grave [tesis]. La Habana: Facultad de Ciencias Médicas "General Calixto García"; 2012.

  10. Valladares Reyes D, Hurtado de Mendoza Amat J, Mendez Rosabal A. Coincidencia clínico patológica en 403 autopsias de pacientes fallecidos por tromboembolismo pulmonar. Rev Cubana Med Milit. 2007 [citado 11 Nov 2010];36(3). Disponible en: http://scielo.sld.cu/scielo.php?script=sci_arttext&pid=S0138 -65572007000300006&lng=es&nrm=iso&tlng=es

  11. García Gómez A, Almeida Correa E, Santamaría Fuentes S, Pérez Pérez O, Gutiérrez Gutiérrez L. Correlación clínica y patológica del tromboembolismo pulmonar. Rev Cubana Med Int Emerg. 2003 [citado 2 Dic 2010];2(4). Disponible en: http://bvs.sld.cu/revistas/mie/vol2_4_03/mie02403.htm

  12. Tamargo Pérez de Corcho PA, Estenoz Esquivel JC. Estudio de morbilidad y mortalidad en el tromboembolismo pulmonar. Rev Cubana Angiol Cir Vasc. 2006 [citado 8 Ago 2012];7(1). Disponible en: http://bvs.sld.cu/revistas/ang/vol7_1_06/ang02106.htm

  13. Rivero Fernández E, Pérez Sarmiento R, Basulto Barroso M, Machado García JL. Tromboembolismo pulmonar en la unidad de cuidados intensivos. Rev Cub Med Int Emerg, 2008;7(2):1147-53.

  14. Berqvist D, Burmark VS, Frisell J, Hallbook T, Lindblad B, Risberg B. Low molecular weight heparin once daily compared with conventional low-dose heparin twice daily. A prospective double-blind multicentre trial on prevention of postoperative thrombosis. Br J Surg. 1986; 73(3):204-8.

  15. Guijarro R, San Román CM, Perelló JI, Nuño E.A study of hospital discharges for venous thromboembolism in the south of Spain. An analysis of 19,170 cases from a regional database from 1998 to 2001. Eur J Intern Med 2005; 16 (4): 279-86.

  16. Avorn J, Winkelmayer WC. Comparing the costs, risks and benefits of competing strategies for the primary prevention of venous thromboembolism. Circulation. 2004; Suppl IV:25-32.

  17. Guyatt GH, Akl EA, Crowther M, Gutterman DD, Schünemann HJ. Antithrombotic therapy and prevention of thrombosis. 9th ed. American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. CHEST. 2012; 141(Suppl 2):747.

  18. Greerts WH, Heit JA, Clagett GP. Prevention of venous thromboembolism. Chest. 2001; 119:132-75.

  19. Villagómez AJ, Carrillo Esper R, Alcántar Luna E, Avelar F, Ayala López E, Bautista Bautista E, et al. Guías para el diagnóstico, prevención y tratamiento de la enfermedad tromboembólica venosa. Rev Mex Anestesiología. 2006;29 (Suppl 2):303-34.

  20. Claggett GP, Anderson FA, Geerts W, Heit JA, Knudson M, Lieberman JR. Prevention of venous thromboembolism. Chest. 1998;114:531-60.

  21. Egger B, Schmid SW, Naef M, Wildi S, Buchler MW. Efficacy and safety of weight-adapted Nadroparin calcium vs heparin sodium in prevention of clinically evident thromboembolic complication in 1 190 general surgical patients. Diag Surg. 2000;17:602-9.

  22. Hettiarachchi RJ, Lok J, Prins MH, Buller HR, Prandoni P. Undiagnosed malignancy in patients with deep vein thrombosis: incidence, risk indicators, and diagnosis. Cancer. 1998;83:180-5.

  23. Samama MM, Cohen AT, Darmon JY. A comparison of Enoxaparin with placebo for the prevention of venous thromboembolism in acutely ill medical patients. N Engl J Med. 1999; 341:793-800.

  24. Leizorovoc A, Cohen AT, Turpie G. Randomized placebo controlled trial of Dalteparin for the prevention of venous thrombembolism in acutely ill medical patients. Circulation. 2004; 110:874-9.

  25. Fraisse F, Holzapfel L, Couland JM. Nadroparin in the prevention of deep vein thrombosis in acute descompensated COPD. Am J Repir Crit Care Med. 2000;161:1109-14.

  26. Cohen AT, Davidson BL, Gallus AS, Lassen MR, Tomkowski W, Turpie AG, et al. Fondaparinux for the prevention of VTE in acutely ill medical patients. Blood. 2003;102(11):15a-16a.

  27. Eriksson BI, Dahl OE, Rosencher N. Dabigatran etexilate versus Enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet. 2007;370:949-56.

  28. Kubitza D, Becka M, Voith B, Zuehlsdorf M, Wensing G. Safety pharmacodynamics and pharmacokinetics of single doses of BAY 59-7939, an oral, direct factor Xa inhibitor. Clin Pharmacol Ther. 2005;78:412-21.

  29. Kubitza D, Becka M, Wensing G, Voith B, Zuehlsdorf M. Safety, pharmacodynamics, and pharmacokinetics of BAY 59-7939 -an oral, direct Factor Xa inhibitor- after multiple dosing in healthy male subjects. Eur J Clin Pharmacol. 2005;61:873-80.

  30. Bengt IE, Borris LC, Friedman RJ, Haas S, Huisman MV Kakkar AK, et al. Rivaroxaban versus Enoxaparin for thromboprophylaxis after hip arthroplasty. N Engl J Med. 2008;358:2765-75.

  31. Mueck W, Eriksson BI, Bauer KA. Population pharmacokinetics and pharmacodynamics of Rivaroxaban -an oral, direct Factor Xa inhibitor- in patients undergoing major orthopaedic surgery. Clin Pharmacokinet. 2008;47:203-16.

  32. Lassen MR, Ageno W, Borris LC, Lieberman JR, Rosencher N, Bandel TJ, et al. Rivaroxaban versus Enoxaparin for thromboprophylaxis after total knee arthroplasty. N Engl J Med. 2008;358:2776-86.

  33. Apostolakis S, Lip G Y, Lane D A, Shantsila E. The Quest for New Anticoagulants: From Clinical Development to Clinical Practice. Cardiovascular Therapeutics.2010; 29 e12-e22.

  34. Warkentin TE. Heparin-induced thrombocitopenia: Pathogenesis and management. Br J Haematol. 2003;121:535-55.




2020     |     www.medigraphic.com